Laidlaw Wealth Management’s Novavax NVAX Stock Holding History

Laidlaw Wealth Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,936	Closed	-$290K	–	396
2022 Q1	$290K	Buy	3,936 +1,223	+45%	+$109K	0.05%	307
2021 Q4	$388K	Buy	+2,713	New	+$466K	0.06%	261

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Laidlaw Wealth Management's NVAX Position: Q2 2022 in Review

Laidlaw Wealth Management sold out of Novavax (NVAX) in Q2 2022, closing a stake of 3,936 shares — an estimated $290K sold.

Laidlaw Wealth Management first reported a position in NVAX in Q4 2021 and held it in 2 quarters. The position peaked at $388K in Q4 2021. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

Laidlaw Wealth Management reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
Laidlaw Wealth Management sold 3,936 Novavax shares in Q2 2022, an estimated $290K.
Laidlaw Wealth Management first reported a position in Novavax in Q4 2021 and held it in 2 quarters.
Laidlaw Wealth Management's Novavax position peaked at $388K in Q4 2021.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Laidlaw Wealth Management's 13F filing for Q2 2022, filed 12 Aug 2022.